The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer

Seminars in Cancer Biology

Volumn 14, Issue 4, 2004, Pages 231-243

  Nachmias, Boaz ^a   Ashhab, Yaqoub ^a   Ben Yehuda, Dina ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

baculovirus inhibitory repeat; BIR; IAP; inhibitor of apoptosis protein; JNK; Jun kinase 1; really interesting new gene; RING; Smac; TNF; TNF related apoptosis inducing ligand; TRIAL; tumor necrosis factor; X linked IAP; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CASPASE; CISPLATIN; COMPLEMENTARY DNA; COMPLEMENTARY RNA; ETOPOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; PACLITAXEL; POLYPHENYLUREA DERIVATIVE; PROTEIN KINASE INHIBITOR; RIBOZYME; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; STAUROSPORINE; STRUCTURAL PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

BACULOVIRUS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MELANOMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 3042660431     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2004.04.002     Document Type: Article

References (142)

1. Schmitt C.A. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer. 3:2003;286-295
2. Schulze-Bergkamen H., Krammer P.H. Apoptosis in cancer - implications for therapy. Semin. Oncol. 31:2004;90-119
3. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1:2000;120-129
4. Rathmell J.C., Thompson C.B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell. 109(Suppl):2002;97-107
5. Reed C.J. Apoptosis and cancer: strategies for integrating programmed cell death. Semin. Hematol. 37:2000;9-16
6. Chen M., Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 7:2002;313-319
7. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene. 22:2003;9030-9040
8. Yin X.M. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 10:2000;161-167
9. Deveraux Q.L., Stennicke H.R., Salvesen G.S., Reed J.C. Endogenous inhibitors of caspases. J. Clin. Immunol. 19:1999;388-398
10. Clem R.J., Sheu T.T., Richter B.W., He W.W., Thornberry N.A., Duckett C.S., et al. c-IAP1 is cleaved by caspases to produce a pro-apoptotic C-terminal fragment. J. Biol. Chem. 276:2001;7602-7608
11. Nachmias B., Ashhab Y., Bucholtz V., Drize O., Kadouri L., Lotem M., et al. Caspase-mediated cleavage converts Livin from an anti-apoptotic to a pro-apoptotic factor: implications for drug-resistant melanoma. Cancer Res. 63:2003;6340-6349
12. Liston P., Fong W.G., Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 22:2003;8568-8580
13. Suzuki Y., Nakabayashi Y., Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8662-8667
14. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., et al. Pleiotropic cell-division defects and apoptosis induced by interference with Survivin function. Nat. Cell Biol. 1:1999;461-466
15. Rothe M., Pan M.G., Henzel W.J., Ayres T.M., Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 83:1995;1243-1252
16. Takahashi R., Deveraux Q., Tamm I., Welsh K., Assa-Munt N., Salvesen G.S., et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273:1998;7787-7790
17. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 104:2001;791-800
18. Chai J., Shiozaki E., Srinivasula S.M., Wu Q., Datta P., Alnemri E.S., et al. Structural basis of caspase-7 inhibition by XIAP. Cell. 104:2001;769-780
19. Huang Y., Park Y.C., Rich R.L., Segal D., Myszka D.G., Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell. 104:2001;781-790
20. Sanna M.G., da Silva Correia J., Ducrey O., Lee J., Nomoto K., Schrantz N., et al. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell Biol. 22:2002;1754-1766
21. Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays. 25:2003;17-24
22. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. Embo J. 18:1999;179-187
23. Hofer-Warbinek R., Schmid J.A., Stehlik C., Binder B.R., Lipp J., de Martin R., et al. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J. Biol. Chem. 275:2000;22064-22068
24. Jesenberger V., Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 3:2002;112-121
25. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 288:2000;874-877
26. MacFarlane M., Merrison W., Bratton S.B., Cohen G.M. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J. Biol. Chem. 277:2002;36611-36616
27. Clemens M.J., Bushell M., Jeffrey I.W., Pain V.M., Morley S.J. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ. 7:2000;603-615
28. Holcik M., Sonenberg N., Korneluk R.G. Internal ribosome initiation of translation and the control of cell death. Trends Genet. 16:2000;469-473
29. Holcik M., Yeh C., Korneluk R.G., Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene. 19:2000;4174-4177
30. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat. Cell Biol. 3:2001;128-133
31. Hegde R., Srinivasula S.M., Zhang Z., Wassell R., Mukattash R., Cilenti L., et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem. 277:2002;432-438
32. Suzuki Y., Takahashi-Niki K., Akagi T., Hashikawa T., Takahashi R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ. 11:2004;208-216
33. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 8:2001;613-621
34. Wu G., Chai J., Suber T.L., Wu J.W., Du C., Wang X., et al. Structural basis of IAP recognition by Smac/DIABLO. Nature. 408:2000;1008-1012
35. Song Z., Yao X., Wu M. Direct interaction between Survivin and Smac/DIABLO is essential for the anti-apoptotic activity of Survivin during taxol-induced apoptosis. J. Biol. Chem. 278:2003;23130-23140
36. Deveraux Q.L., Leo E., Stennicke H.R., Welsh K., Salvesen G.S., Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. Embo J. 18:1999;5242-5251
37. Harvey A.J., Soliman H., Kaiser W., Miller L.K. Anti- and pro-apoptotic activities of baculovirus and Drosophila IAPs in an insect cell line. Cell Death Differ. 4:1997;733-744
38. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 279:2004;5405-5412
39. Gagnon V., St-Germain M.E., Parent S., Asselin E. Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int. J. Oncol. 23:2003;803-810
40. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood. 98:2001;2603-2614
41. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58:1998;5071-5074
42. Kawasaki H., Toyoda M., Shinohara H., Okuda J., Watanabe I., Yamamoto T., et al. Expression of Survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 91:2001;2026-2032
43. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., et al. Expression of Survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer. 95:2001;92-95
44. Ikeguchi M., Yamaguchi K., Kaibara N. Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol. 24:2003;40-45
45. Ikeguchi M., Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br. J. Cancer. 87:2002;883-887
46. Grabowski P., Kuhnel T., Muhr-Wilkenshoff F., Heine B., Stein H., Hopfner M., et al. Prognostic value of nuclear Survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer. 88:2003;115-119
47. Wurl P., Kappler M., Meye A., Bartel F., Kohler T., Lautenschlager C., et al. Co-expression of Survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet. 359:2002;943-945
48. Kappler M., Kohler T., Kampf C., Diestelkotter P., Wurl P., Schmitz M., et al. Increased Survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer. 95:2001;360-363
49. Chakravarti A., Noll E., Black P.M., Finkelstein D.F., Finkelstein D.M., Dyson N.J., et al. Quantitatively determined Survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20:2002;1063-1068
50. Kleinschmidt-DeMasters B.K., Heinz D., McCarthy P.J., Bobak J.B., Lillehei K.O., Shroyer A.L., et al. Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch. Pathol. Lab. Med. 127:2003;826-833
51. Lu C.D., Altieri D.C., Tanigawa N. Expression of a novel antiapoptosis gene, Survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58:1998;1808-1812
52. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., Shimosegawa T. Expression of Survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 92:2001;271-278
53. Ikeguchi M., Ueda T., Sakatani T., Hirooka Y., Kaibara N. Expression of Survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn. Mol. Pathol. 11:2002;33-40
54. Saitoh Y., Yaginuma Y., Ishikawa M. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int. J. Oncol. 15:1999;137-141
55. Koch C.A., Vortmeyer A.O., Diallo R., Poremba C., Giordano T.J., Sanders D., et al. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur. J. Endocrinol. 146:2002;381-388
56. Kennedy S.M., O'Driscoll L., Purcell R., Fitz-Simons N., McDermott E.W., Hill A.D., et al. Prognostic importance of Survivin in breast cancer. Br. J. Cancer. 88:2003;1077-1083
57. Trieb K., Lehner R., Stulnig T., Sulzbacher I., Shroyer K.R. Survivin expression in human osteosarcoma is a marker for survival. Eur. J. Surg. Oncol. 29:2003;379-382
58. Yoshida H., Ishiko O., Sumi T., Matsumoto Y., Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int. J. Oncol. 19:2001;537-542
59. Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawa I. Expression of Survivin is associated with malignant potential in epithelial ovarian carcinoma. Int. J. Mol. Med. 10:2002;211-216
60. Sui L., Dong Y., Ohno M., Watanabe Y., Sugimoto K., Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int. J. Oncol. 21:2002;315-320
61. Zaffaroni N., Pennati M., Colella G., Perego P., Supino R., Gatti L., et al. Expression of the anti-apoptotic gene Survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 59:2002;1406-1412
62. Cohen C., Lohmann C.M., Cotsonis G., Lawson D., Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod. Pathol. 16:2003;574-583
63. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 60:2000;5659-5666
64. Li J., Feng Q., Kim J.M., Schneiderman D., Liston P., Li M., et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology. 142:2001;370-380
65. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., Altieri D.C. Tumor content of the antiapoptosis molecule Survivin and recurrence of bladder cancer. N. Engl. J. Med. 341:1999;452-453
66. Ku J.H., Kwak C., Lee H.S., Park H.K., Lee E., Lee S.E. Expression of Survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J. Urol. 171:2004;631-635
67. Schultz I.J., Kiemeney L.A., Witjes J.A., Schalken J.A., Willems J.L., Swinkels D.W., et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. anti-cancer Res. 23:2003;3327-3331
68. Shariat S.F., Casella R., Khoddami S.M., Hernandez G., Sulser T., Gasser T.C., et al. Urine detection of Survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J. Urol. 171:2004;626-630
69. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., Altieri D.C. Urine detection of Survivin and diagnosis of bladder cancer. JAMA. 285:2001;324-328
70. Nakanishi K., Tominaga S., Hiroi S., Kawai T., Aida S., Kasamatsu H., et al. Expression of Survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 441:2002;559-563
71. Lehner R., Lucia M.S., Jarboe E.A., Orlicky D., Shroyer A.L., McGregor J.A. Immunohistochemical localization of the IAP protein Survivin in bladder mucosa and transitional cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 10:2002;134-138
72. Ashhab Y., Alian A., Polliack A., Panet A., Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 495:2001;56-60
73. Gazzaniga P., Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., et al. Expression and prognostic significance of Livin, Survivin and other apoptosis-related genes in the progression of superficial bladder cancer. Ann. Oncol. 14:2003;85-90
74. Bilim V., Kasahara T., Hara N., Takahashi K., Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer. 103:2003;29-37
75. Ferreira C.G., van der Valk P., Span S.W., Jonker J.M., Postmus P.E., Kruyt F.A., et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. 12:2001;799-805
76. Escuin D., Rosell R. The anti-apoptosis Survivin gene and its role in human cancer: an overview. Clin. Lung Cancer. 1:1999;138-143
77. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., et al. A novel anti-apoptosis gene: re-expression of Survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17:1999;2100-2104
78. Hofmann H.S., Simm A., Hammer A., Silber R.E., Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J. Cancer Res. Clin. Oncol. 128:2002;554-560
79. Ikehara M., Oshita F., Kameda Y., Ito H., Ohgane N., Suzuki R., et al. Expression of Survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol. Rep. 9:2002;835-838
80. Falleni M., Pellegrini C., Marchetti A., Oprandi B., Buttitta F., Barassi F., et al. Survivin gene expression in early-stage non-small cell lung cancer. J. Pathol. 200:2003;620-626
81. Ekedahl J., Joseph B., Grigoriev M.Y., Muller M., Magnusson C., Lewensohn R., et al. Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp. Cell Res. 279:2002;277-290
82. Yang L., Mashima T., Sato S., Mochizuki M., Sakamoto H., Yamori T., et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 63:2003;831-837
83. Hu Y., Cherton-Horvat G., Dragowska V., Baird S., Korneluk R.G., Durkin J.P., et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 9:2003;2826-2836
84. Ferreira C.G., van der Valk P., Span S.W., Ludwig I., Smit E.F., Kruyt F.A., et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin. Cancer Res. 7:2001;2468-2474
85. McEleny K.R., Watson R.W., Coffey R.N., O'Neill A.J., Fitzpatrick J.M. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 51:2002;133-140
86. Krajewska M., Krajewski S., Banares S., Huang X., Turner B., Bubendorf L., et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. 9:2003;4914-4925
87. Kaur P., Kallakury B.S., Sheehan C.E., Fisher H.A., Kaufman R.P. Jr., Ross J.S. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol. Lab. Med. 128:2004;39-43
88. Shariat S.F., Lotan Y., Saboorian H., Khoddami S.M., Roehrborn C.G., Slawin K.M., et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 100:2004;751-757
89. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., et al. Prognostic significance of Survivin expression in diffuse large B-cell lymphomas. Blood. 96:2000;1921-1925
90. Martinez A., Bellosillo B., Bosch F., Ferrer A., Marce S., Villamor N., et al. Nuclear Survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am. J. Pathol. 164:2004;501-510
91. Mori N., Yamada Y., Hata T., Ikeda S., Yamasaki Y., Tomonaga M., et al. Expression of Survivin in HTLV-I-infected T-cell lines and primary ATL cells. Biochem. Biophys. Res. Commun. 282:2001;1110-1113
92. Paydas S., Tanriverdi K., Yavuz S., Disel U., Sahin B., Burgut R. Survivin and aven: two distinct anti-apoptotic signals in acute leukemias. Ann. Oncol. 14:2003;1045-1050
93. Badran A., Yoshida A., Wano Y., Imamura S., Kawai Y., Tsutani H., et al. Expression of the anti-apoptotic gene Survivin in chronic myeloid leukemia. anti-cancer Res. 23:2003;589-592
94. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. Nat. Med. 3:1997;917-921
95. Sugawara M., Matsuzuka F., Fukata S., Kuma K., Moatamed F., Haugen B.R. Excessive Survivin expression in thyroid lymphomas. Hum. Pathol. 33:2002;524-527
96. Badran A., Yoshida A., Wano Y., Mutoh M., Imamura S., Yamashita T. Expression of the anti-apoptotic gene Survivin in myelodysplastic syndrome. Int. J. Oncol. 22:2003;59-64
97. Kitada S., Zapata J.M., Andreeff M., Reed J.C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 96:2000;393-397
98. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6:2000;1796-1803
99. Adida C., Recher C., Raffoux E., Daniel M.T., Taksin A.L., Rousselot P., et al. Expression and prognostic significance of Survivin in de novo acute myeloid leukaemia. Br. J. Haematol. 111:2000;196-203
100. Carter B.Z., Kornblau S.M., Tsao T., Wang R.Y., Schober W.D., Milella M., et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 102:2003;4179-4186
101. Kashkar H., Haefs C., Shin H., Hamilton-Dutoit S.J., Salvesen G.S., Kronke M. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J. Exp. Med. 198:2003;341-347
102. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J.M., Hossfeld D.K., et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6 associated with mucosa-associated lymphoid tissue lymphomas. Blood. 93:1999;3601-3609
103. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene. 22:2003;3138-3151
104. Hussein M.R., Haemel A.K., Wood G.S. Apoptosis and melanoma: molecular mechanisms. J. Pathol. 199:2003;275-288
105. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma. J. Invest. Dermatol. 113:1999;1076-1081
106. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression of the apoptosis inhibitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab. Invest. 79:1999;1121-1126
107. Chiodino C., Cesinaro A.M., Ottani D., Fantini F., Giannetti A., Trentini G.P., et al. Communication: expression of the novel inhibitor of apoptosis Survivin in normal and neoplastic skin. J. Invest. Dermatol. 113:1999;415-418
108. Gradilone A., Gazzaniga P., Ribuffo D., Scarpa S., Cigna E., Vasaturo F., et al. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 21:2003;306-312
109. Helmbach H., Rossmann E., Kern M.A., Schadendorf D. Drug-resistance in human melanoma. Int. J. Cancer. 93:2001;617-622
110. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., Altieri D.C. Suppression of Survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 63:2003;230-235
111. Mesri M., Wall N.R., Li J., Kim R.W., Altieri D.C. Cancer gene therapy using a Survivin mutant adenovirus. J. Clin. Invest. 108:2001;981-990
112. Allen S.M., Florell S.R., Hanks A.N., Alexander A., Diedrich M.J., Altieri D.C., et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res. 63:2003;567-572
113. Amelsberg M., Amelsberg A., Ainsworth M.A., Hogan D.L., Isenberg J.I. Cyclic adenosine-3′, 5′-monophosphate production is greater in rabbit duodenal crypt than in villus cells. Scand. J. Gastroenterol. 31:1996;233-239
114. Nishihara H., Kizaka-Kondoh S., Insel P.A., Eckmann L. Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc. Natl. Acad. Sci. U.S.A. 100:2003;8921-8926
115. Zhang T., Otevrel T., Gao Z., Ehrlich S.M., Fields J.Z., Boman B.M. Evidence that APC regulates Survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61:2001;8664-8667
116. Mansouri A., Zhang Q., Ridgway L.D., Tian L., Claret F.X. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol. Res. 13:2003;399-404
117. Notarbartolo M., Cervello M., Poma P., Dusonchet L., Meli M., D'Alessandro N. Expression of the IAPs in multidrug resistant tumor cells. Oncol. Rep. 11:2004;133-136
118. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10057-10062
119. Wang Q., Wang X., Evers B.M. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J. Biol. Chem. 278:2003;51091-51099
120. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 188:1998;211-216
121. Tang G., Minemoto Y., Dibling B., Purcell N.H., Li Z., Karin M., et al. Inhibition of JNK activation through NF-kappaB target genes. Nature. 414:2001;313-317
122. Sommer K.W., Schamberger C.J., Schmidt G.E., Sasgary S., Cerni C. Inhibitor of apoptosis protein (IAP) Survivin is upregulated by oncogenic c-H-Ras. Oncogene. 22:2003;4266-4280
123. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., et al. Human Survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2002;2613-2622
124. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic Survivin gene by wild type p53. J. Biol. Chem. 277:2002;3247-3257
125. Hong X., Lei L., Glas R. Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. J. Exp. Med. 197:2003;1731-1743
126. Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, et al. Ribozyme-mediated down-regulation of Survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004.
127. Ansell S.M., Arendt B.K., Grote D.M., Jelinek D.F., Novak A.J., Wellik L.E., et al. Inhibition of Survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia. 18:2004;616-623
128. Carter B.Z., Milella M., Tsao T., McQueen T., Schober W.D., Hu W., et al. Regulation and targeting of anti-apoptotic XIAP in acute myeloid leukemia. Leukemia. 17:2003;2081-2089
129. Crnkovic-Mertens I., Hoppe-Seyler F., Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the Livin/ML-IAP/KIAP gene. Oncogene. 22:2003;8330-8336
130. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277:2002;44236-44243
131. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anti-cancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8:2002;808-815
132. Franklin M.C., Kadkhodayan S., Ackerly H., Alexandru D., Distefano M.D., Elliott L.O., et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry. 42:2003;8223-8231
133. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 5:2004;25-35
134. Wu T.Y., Wagner K.W., Bursulaya B., Schultz P.G., Deveraux Q.L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 10:2003;759-767
135. O'Connor D.S., Wall N.R., Porter A.C., Altieri D.C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2:2002;43-54
136. Blanc-Brude O.P., Yu J., Simosa H., Conte M.S., Sessa W.C., Altieri D.C. Inhibitor of apoptosis protein Survivin regulates vascular injury. Nat. Med. 8:2002;987-994
137. Rohayem J., Diestelkoetter P., Weigle B., Oehmichen A., Schmitz M., Mehlhorn J., et al. Antibody response to the tumor-associated inhibitor of apoptosis protein Survivin in cancer patients. Cancer Res. 60:2000;1815-1817
138. Yagihashi A., Asanuma K., Nakamura M., Araya J., Mano Y., Torigoe T., et al. Detection of anti-Survivin antibody in gastrointestinal cancer patients. Clin. Chem. 47:2001;1729-1731
139. Yagihashi A., Asanuma K., Tsuji N., Torigoe T., Sato N., Hirata K., et al. Detection of anti-Livin antibody in gastrointestinal cancer patients. Clin. Chem. 49:2003;1206-1208
140. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, Straten PP, et al. Identification of novel Survivin-derived CTL epitopes. Cancer Biol Ther 2004;3.
141. Reker S., Becker J.C., Svane I.M., Ralfkiaer E., Straten P.T., Andersen M.H. HLA-B35-restricted immune responses against Survivin in cancer patients. Int. J. Cancer. 108:2004;937-941
142. Andersen M.H., Reker S., Becker J.C., thor Straten P. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J. Invest. Dermatol. 122:2004;392-399